Modelling atypical CYP3A4 kinetics: principles and pragmatism.

[1]  I. H. Segel.  Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems , 1975 .

[2]  D. Herries.  Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems: By Irwin H. Segel. John Wiley & Sons, 1975. pp xxii + 957. Boards, £15.00 , 1976 .

[3]  T. Kost,et al.  CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. , 1995, Archives of biochemistry and biophysics.

[4]  F. Guengerich,et al.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.

[5]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[6]  J. Halpert,et al.  Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. Ring,et al.  Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. , 1998, Pharmacogenetics.

[8]  T. Baillie,et al.  Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. , 1999, The Biochemical journal.

[9]  J B Houston,et al.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. , 1999, British journal of clinical pharmacology.

[10]  R. Miller,et al.  Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. , 1999, The Journal of pharmacology and experimental therapeutics.

[11]  R. Miller,et al.  Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[12]  J. Lin,et al.  Sense and nonsense in the prediction of drug-drug interactions. , 2000, Current drug metabolism.

[13]  J B Houston,et al.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[14]  S. D. Turner,et al.  Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[15]  A. D. Rodrigues,et al.  Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[16]  J. Vacca,et al.  P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[17]  J. Halpert,et al.  Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. , 2001, Biochemistry.

[18]  A. D. Rodrigues,et al.  Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[19]  T. Baillie,et al.  A Kinetic Model for the Metabolic Interaction of Two Substrates at the Active Site of Cytochrome P450 3A4* , 2001, Journal of Biological Chemistry.

[20]  A. D. Rodrigues,et al.  Drug-drug interactions , 2001, Atkinson's Principles of Clinical Pharmacology.

[21]  A. D. Rodrigues,et al.  Enzyme kinetics of cytochrome P450-mediated reactions. , 2012, Current drug metabolism.

[22]  Shiew-Mei Huang,et al.  Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[23]  B. Ring,et al.  Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[24]  A. Galetin,et al.  Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[25]  Timothy S Tracy,et al.  Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. , 2003, Archives of biochemistry and biophysics.

[26]  D. Greenblatt,et al.  In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[27]  S. Boyer,et al.  Generation and Evaluation of a CYP2C9 Heteroactivation Pharmacophore , 2003, Journal of Pharmacology and Experimental Therapeutics.

[28]  J. Halpert,et al.  Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. , 2003, Archives of biochemistry and biophysics.

[29]  A. Galetin,et al.  Progress Towards Prediction of Human Pharmacokinetic Parameters from In Vitro Technologies , 2003, Drug metabolism reviews.

[30]  M. Hata,et al.  Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. , 2003, Biochemistry.

[31]  S. Boyer,et al.  In Vivo CYP3A4 Heteroactivation Is a Possible Mechanism for the Drug Interaction between Felbamate and Carbamazepine , 2003, Journal of Pharmacology and Experimental Therapeutics.

[32]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[33]  Amy Roe,et al.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[34]  A. Galetin,et al.  Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[35]  A. Galetin,et al.  Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[36]  R. Obach,et al.  Drug Metabolizing Enzymes : Cytochrome P450 and Other Enzymes in Drug Discovery and Development , 2003 .

[37]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[38]  Kiyomi Ito,et al.  Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. , 2004, British journal of clinical pharmacology.

[39]  M. Yoon,et al.  “Allosterism” in the Elementary Steps of the Cytochrome P450 Reaction Cycle , 2004, Drug metabolism reviews.

[40]  S. Boye,et al.  Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. , 2004, Biochemistry.

[41]  Aleksandra Galetin,et al.  UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES , 2004, Drug Metabolism and Disposition.

[42]  W. Atkins.  Implications of the allosteric kinetics of cytochrome P450s. , 2004, Drug discovery today.

[43]  Yuichi Sugiyama,et al.  Quantitative Prediction of In Vivo Drug-Drug Interactions from In Vitro Data Based on Physiological Pharmacokinetics: Use of Maximum Unbound Concentration of Inhibitor at the Inlet to the Liver , 2000, Pharmaceutical Research.

[44]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[45]  A. Galetin,et al.  Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. , 2004, Drug metabolism and disposition: the biological fate of chemicals.